Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas

NCT00356031 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00356031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
March 31, 2010
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosarcoma, fibrous histiocytoma, leiomyosarcoma, liposarcoma, soft tissue sarcoma, synovial sarcoma